The company launched the Osteo-Site Vertebral Balloon for vertebral augmentation, completing IZI's line of Vertebral Compression Fracture treatment options.
The company will use the capital to support ongoing clinical trials of its injectable Discogenic Cell Therapy (IDCT) for lumbar degenerative disc disease.
The company raises the funds through a non-brokered private placement. The proceeds will fund initiatives like securing FDA approval for clinical trials.
The company announced the U.S. commercial launch of the Matriform Si, a silicated synthetic bone graft substitute designed and cleared for spinal fusion.